A number of research have discovered semaglutide (out there underneath the model names Wegovy and Ozempic) lowered the danger of loss of life in individuals who had been overweight or chubby and had heart problems with out diabetes.

Individuals who took semaglutide died at a decrease price from all causes, as properly from cardiovascular causes and Covid-19, researchers discovered.

The drug was additionally discovered to enhance coronary heart failure signs.

Responding to analysis revealed in JACC, the flagship journal of the American School of Cardiology, Professor Harlan M Krumholz from the Yale Faculty of Drugs, stated: “Semaglutide, maybe by enhancing cardiometabolic well being, has far-reaching advantages past what we initially imagined.”

He added: “These ground-breaking medicines are poised to revolutionise cardiovascular care and will dramatically improve cardiovascular well being.”

A number of stories additionally quoted Professor Krumholz saying: “Is it a fountain of youth?”

He stated: “I might say for those who’re enhancing somebody’s cardiometabolic well being considerably, then you’re placing them ready to dwell longer and higher.

“It’s not simply avoiding coronary heart assaults. These are well being promoters. It wouldn’t shock me that enhancing folks’s well being this manner truly slows down the ageing course of.”

The research, offered on the European Society of Cardiology Convention 2024 in London, had been produced from the Choose trial which studied 17,604 folks aged 45 or older who had been chubby or overweight and had established heart problems however not diabetes.

They acquired 2.4 mg of semaglutide or a placebo and had been tracked for greater than three years.

A complete of 833 contributors died through the examine with 58% of the deaths had been associated to cardiovascular causes and 42% from others.

An infection was the commonest trigger loss of life past cardiovascular, however it occurred at a decrease price within the semaglutide group than the placebo group.

Folks utilizing the weight-loss drug had been simply as prone to catch Covid-19, however they had been much less prone to die from it – 2.6% dying amongst these on semaglutide versus 3.1% on the placebo.

Researchers discovered girls skilled fewer main opposed cardiovascular occasions, however semaglutide “constantly lowered the danger” of opposed cardiovascular outcomes no matter intercourse.

Dr Benjamin Scirica, lead creator of one of many research and a professor of cardiovascular medication at Harvard Medical Faculty, stated: “The sturdy discount in non-cardiovascular loss of life, and significantly infections deaths, was stunning and maybe solely detectable due to the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that chubby and weight problems will increase the danger of loss of life as a consequence of many etiologies, which might be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medication doctor at Brigham and Girls’s Hospital, praised the researchers for adapting the examine to have a look at Covid-19 when the pandemic began.

He stated the findings that the weight-loss drug to scale back Covid-19 mortality charges had been “akin to a vaccine in opposition to the oblique results of a pathogen.”

He stated: “Folks with coronary artery illness who had deadly myocardial infarctions precipitated by the physiological stress (or) inflammatory response induced by Covid-19 (or any an infection) might have averted these outcomes, had been their threat profiles decrease when contaminated.

“By including documentation of Covid-19 instances and mortality, the Choose trial has yielded necessary insights concerning the epidemiology of COVID-19 and the very nature of infectious illness mortality.”